(Q35851824)

10 August 2017

Bio-effect model applied to 131I radioimmunotherapy of refractory non-Hodgkin's lymphoma (English)

1 reference

10 August 2017

Peter L Roberson

1

1 reference

10 August 2017

Hanan Amro

2

1 reference

10 August 2017

Scott J Wilderman

3

1 reference

10 August 2017

Anca M Avram

4

1 reference

10 August 2017

Mark S Kaminski

5

1 reference

10 August 2017

Matthew J Schipper

6

1 reference

10 August 2017

Yuni K Dewaraja

7

1 reference

10 August 2017

21 December 2010

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

10 August 2017

1 reference

10 August 2017

38

1 reference

10 August 2017

5

1 reference

10 August 2017

874-883

1 reference

131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling

10 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3312018

Method for Fast CT/SPECT-Based 3D Monte Carlo Absorbed Dose Computations in Internal Emitter Therapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3312018

Use of integrated SPECT/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3312018

Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3312018

Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3312018

Implications of nonuniform tumor doses for radioimmunotherapy.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3312018

Low dose hyper-radiosensitivity and increased radioresistance in mammalian cells

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3312018

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3312018

The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy.

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3312018

The linear-quadratic formula and progress in fractionated radiotherapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3312018

The radiobiology of targeted radiotherapy

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3312018

The radioisotope contributes significantly to the activity of radioimmunotherapy.

11 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1699-3

Correction to Kasibhatla et al. How much radiation is the chemotherapy worth in advanced head and neck cancer? (Int j radiat oncol biol phys 2007;68:1491-1495).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1699-3

Use of the concept of equivalent biologically effective dose (BED) to quantify the contribution of hyperthermia to local tumor control in radiohyperthermia cervical cancer trials, and comparison with radiochemotherapy results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1699-3

Methodology to incorporate biologically effective dose and equivalent uniform dose in patient-specific 3-dimensional dosimetry for non-Hodgkin lymphoma patients targeted with 131I-tositumomab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1699-3

Correlating metabolic activity with cellular proliferation in follicular lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1699-3

Approximations to the Log-Likelihood Function in the Nonlinear Mixed-Effects Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-010-1699-3

Radiobiological aspects of low dose rates in radioimmunotherapy

21 January 2018

1 reference

12 December 2020

Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience

1 reference

12 December 2020

The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma

1 reference

12 December 2020

Radiobiologic studies of low-dose-rate 90Y-lymphoma therapy

1 reference

12 December 2020

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

12 December 2020

10.1007/S00259-010-1699-3

Identifiers

DOI

1 reference

10 August 2017

1 reference

10 August 2017

PubMed publication ID

21174088

1 reference